- Accelerated bookbuild offering amounting to €32.7m.
- Proceeds will be used to finance further clinical trials, to support the global roll-out of its products and to fund the expansion of manufacturing capacity.
- Kempen & Co acted as Joint Bookrunner in the transaction.
The investment services and investment institutions mentioned on the website may not be available in your jurisdiction or to anyone other than professional investors. More information about the countries where these investment institutions are registered and the persons to whom they may be offered can be found on the website.